Souhaitez-vous accéder aux communiqués récents ?

Cevira® advances towards Phase 3 for treatment in patients with cervical high grade lesions (HSIL) Oslo, Norway, 7 January 2015: Photocure ASA (OSE:PHO), a specialty pharmaceutical company focused...

Kjetil Hestdal, President and CEO of Photocure, has today, December 23th 2014, exercised 37 500 share options in Photocure ASA, at the strike price of NOK 18.30. After the transaction, Kjetil...

Oslo, Norway, 22th December 2014: Photocure ASA (OSE: PHO), a specialty pharmaceutical company focused on photodynamic technologies in dermatology and cancer, provides an update on business...

Oslo, Norway, 6 November 2014: Photocure (OSE: PHO), a Norwegian specialty pharmaceutical company focused on photodynamic technologies in dermatology and cancer, announces its results for third...

Phase 2b results demonstrate significant and sustained efficacy in treating human papilloma virus and precancerous lesions of the cervix Oslo, Norway, 4 November 2014:  Photocure ASA (OSE: PHO), a...

Photocure will present its third quarter report on Thursday 6 November 2014 at Hotel Continental, Oslo, Norway. The presentation will begin at 08:30 (CET) and representatives from the company will...

Cysview® improves detection of Non-Muscle Invasive Bladder Cancer (NMIBC) beyond that achieved with current standard of care Oslo, Norway, 23 September 2014:  Photocure ASA (OSE: PHO), a specialty...

Oslo, Norway, 26 August 2014: Photocure (OSE: PHO), a Norwegian specialty pharmaceutical company focused on photodynamic technologies in dermatology and cancer, announces its results for second...

Oslo, Norway, 18 August 2014: Photocure ASA (OSE: PHO), a specialty pharmaceutical company focused on photodynamic technologies in dermatology and cancer, announces today that Photocure and Salix...

Photocure will present its second quarter report on Tuesday 26 August 2014 at Hotel Continental, Oslo, Norway. The presentation will begin at 08:30 (CET) and representatives from the company will...